Literature DB >> 23107730

Red mold dioscorea: a potentially safe traditional function food for the treatment of hyperlipidemia.

Chien-Li Chen1, Tzu-Ming Pan.   

Abstract

A study was undertaken to evaluate whether the interaction between Monascus-fermented products and lovastatin contributes to increased risk of rhabdomyolysis. Rhabdomyolysis is a potentially dangerous side effect of statin drugs. In this study with hyperlipidemic hamsters fed lovastatin only, lovastatin with 1-fold red mold dioscorea (RMD), and lovastatin, the functional components of red mold fermented products, HMG-CoA reductase inhibitors, did not exacerbate pre-existing diseases, and actually helped in improving existing disease conditions, respectively, as compared with the control. Administration of RMD, alone or in combination with lovastatin did not cause significant rhabdomyolysis as assessed by measuring the levels of creatinine phosphokinase. Further, we did not find any study that clearly implicates the involvement of RMD, which have long been considered a food product, in liver and kidney toxicity. RMD alone or in combination with lovastatin, does not increase the risk of rhabdomyolysis, even when administered at a high dosage (including HMG-CoA reductase inhibitors >75 mg/day/adult).
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23107730     DOI: 10.1016/j.foodchem.2012.03.019

Source DB:  PubMed          Journal:  Food Chem        ISSN: 0308-8146            Impact factor:   7.514


  3 in total

1.  A randomized, double-blind clinical study to determine the effect of ANKASCIN 568 plus on blood glucose regulation.

Authors:  Yin-Ruei Wang; Sheng-Fu Liu; You-Cheng Shen; Chien-Li Chen; Chine-Ning Huang; Tzu-Ming Pan; Chin-Kun Wang
Journal:  J Food Drug Anal       Date:  2016-07-30       Impact factor: 6.157

2.  Effects of red mold dioscorea with pioglitazone, a potentially functional food, in the treatment of diabetes.

Authors:  Chien-Li Chen; Tzu-Ming Pan
Journal:  J Food Drug Anal       Date:  2015-07-21       Impact factor: 6.157

3.  A randomized, double-blind clinical study of the effects of Ankascin 568 plus on blood lipid regulation.

Authors:  Sheng-Fu Liu; Yin-Ruei Wang; You-Cheng Shen; Chien-Li Chen; Chine-Ning Huang; Tzu-Ming Pan; Chin-Kun Wang
Journal:  J Food Drug Anal       Date:  2017-06-01       Impact factor: 6.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.